MEZZION PHARMA CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38,700 KRW | +0.39% |
|
+5.16% | -0.77% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 785,088 | 1,665,449 | 1,563,338 | 1,932,235 | 347,646 | 1,153,908 |
| Enterprise Value (EV) 1 | 724,919 | 1,627,887 | 1,519,338 | 1,889,061 | 318,961 | 1,096,162 |
| P/E ratio | -40.5 x | -71.2 x | -110 x | -142 x | -9.57 x | -86.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 41.1 x | 88 x | 54.6 x | 72.5 x | 11.3 x | 36.4 x |
| EV / Revenue | 38 x | 86 x | 53.1 x | 70.9 x | 10.4 x | 34.6 x |
| EV / EBITDA | -33.4 x | -70.5 x | -249 x | -124 x | -14.7 x | -84.7 x |
| EV / FCF | -117 x | -75.8 x | -137 x | -108 x | -74.4 x | -61 x |
| FCF Yield | -0.86% | -1.32% | -0.73% | -0.92% | -1.34% | -1.64% |
| Price to Book | 13.8 x | 38.9 x | 27.5 x | 30.8 x | 13.2 x | 18.8 x |
| Nbr of stocks (in thousands) | 25,601 | 26,118 | 26,678 | 26,701 | 26,742 | 29,587 |
| Reference price 2 | 30,667 | 63,767 | 58,600 | 72,367 | 13,000 | 39,000 |
| Announcement Date | 21/03/19 | 19/03/20 | 23/03/21 | 23/03/22 | 23/03/23 | 18/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 19,088 | 18,931 | 28,634 | 26,654 | 30,726 | 31,721 |
| EBITDA 1 | -21,698 | -23,093 | -6,098 | -15,212 | -21,673 | -12,942 |
| EBIT 1 | -21,926 | -24,425 | -7,531 | -16,798 | -23,331 | -14,489 |
| Operating Margin | -114.87% | -129.02% | -26.3% | -63.02% | -75.93% | -45.68% |
| Earnings before Tax (EBT) 1 | -20,824 | -22,220 | -12,836 | -13,026 | -35,910 | -12,480 |
| Net income 1 | -18,876 | -23,251 | -13,829 | -13,603 | -36,298 | -12,728 |
| Net margin | -98.89% | -122.82% | -48.3% | -51.03% | -118.13% | -40.13% |
| EPS 2 | -757.5 | -895.2 | -532.0 | -509.7 | -1,358 | -451.0 |
| Free Cash Flow 1 | -6,219 | -21,479 | -11,123 | -17,413 | -4,290 | -17,965 |
| FCF margin | -32.58% | -113.46% | -38.85% | -65.33% | -13.96% | -56.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 21/03/19 | 19/03/20 | 23/03/21 | 23/03/22 | 23/03/23 | 18/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 60,169 | 37,562 | 44,000 | 43,173 | 28,685 | 57,747 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -6,219 | -21,479 | -11,123 | -17,413 | -4,290 | -17,965 |
| ROE (net income / shareholders' equity) | -34.2% | -46.4% | -27.8% | -22.7% | -81.5% | -29% |
| ROA (Net income/ Total Assets) | -18.4% | -22.8% | -7% | -13.2% | -21.1% | -12.4% |
| Assets 1 | 102,688 | 102,000 | 197,601 | 103,370 | 171,702 | 102,731 |
| Book Value Per Share 2 | 2,226 | 1,640 | 2,129 | 2,352 | 981.0 | 2,075 |
| Cash Flow per Share 2 | 1,148 | 599.0 | 1,344 | 907.0 | 1,099 | 1,359 |
| Capex 1 | 572 | 1,098 | 774 | 358 | 768 | 529 |
| Capex / Sales | 3% | 5.8% | 2.7% | 1.34% | 2.5% | 1.67% |
| Announcement Date | 21/03/19 | 19/03/20 | 23/03/21 | 23/03/22 | 23/03/23 | 18/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -0.77% | 836M | |
| +3.57% | 69.85B | |
| +11.77% | 8.98B | |
| -14.44% | 4.89B | |
| +41.60% | 4.44B | |
| +5.96% | 3.95B | |
| +21.18% | 2.49B | |
| -19.32% | 2.4B | |
| -27.04% | 2.28B | |
| +7.97% | 1.96B |
- Stock Market
- Equities
- A140410 Stock
- Financials Mezzion Pharma Co.,Ltd.
